Literature DB >> 25121376

Age appropriate screening for cancer: evidence-based practice in the United States of America.

T S Pandey1.   

Abstract

Cancer screening is a well established and integral part of routine care in the Western world including United States. Men and women are recommended to get age-specific screening for common cancers like breast, cervical, prostate, and colon. The goal of screening is primary and secondary prevention. Cancer prevention and early detection of cancers has been shown to improve survival rates and decrease mortality by prompt appropriate treatment. This article serves to outline the current guidelines in the United States for cancer screening and the evidence for them as well as discusses the possibility of a similar model of care in India as well as barriers to such a screening program for cancer. The evidence was mostly obtained from systematic reviews done by the United States Preventive Services Task Force guidelines and other peer institutions like American Cancer Society and Agency for Healthcare Research and Quality.

Entities:  

Mesh:

Year:  2014        PMID: 25121376     DOI: 10.4103/0022-3859.138813

Source DB:  PubMed          Journal:  J Postgrad Med        ISSN: 0022-3859            Impact factor:   1.476


  3 in total

1.  Multi-analyte assays and early detection of common cancers.

Authors:  Robert P Young; Timothy Christmas; Raewyn J Hopkins
Journal:  J Thorac Dis       Date:  2018-07       Impact factor: 2.895

2.  Cervical Cancer Screening Program by Visual Inspection: Acceptability and Feasibility in Health Insurance Companies.

Authors:  Apollinaire G Horo; Judith Didi-Kouko Coulibaly; Abdoul Koffi; Boris Tchounga; Konan Seni; Kacou Edèle Aka; Mamourou Kone
Journal:  Obstet Gynecol Int       Date:  2015-06-18

3.  Assessment and model guided cancer screening promotion by village doctors in China: a randomized controlled trial protocol.

Authors:  Rui Feng; Xingrong Shen; Jing Chai; Penglai Chen; Jing Cheng; Han Liang; Ting Zhao; Rui Sha; Kaichun Li; Debin Wang
Journal:  BMC Cancer       Date:  2015-10-12       Impact factor: 4.430

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.